Online citations, reference lists, and bibliographies.
← Back to Search

Optimization Of Plasmid Vectors For High-level Expression In Lung Epithelial Cells.

N. Yew, D. Wysokenski, K. Wang, R. Ziegler, J. Marshall, D. McNeilly, M. Cherry, W. Osburn, S. Cheng
Published 1997 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Nonviral gene therapy approaches use a plasmid vector to express the desired transgene. We have systematically examined several regulatory elements within plasmid vectors that govern gene expression, e.g., the promoter, enhancer, intron, and polyadenylation signal, by constructing a series of plasmids that differed only in the particular sequence element being evaluated. Of the several promoters and polyadenylation signal sequences that were tested, the human cytomegalovirus (CMV) immediate early gene promoter and the addition of polyadenylation signal sequences from the bovine growth hormone (BGH) gene or rabbit beta-globin gene produced the highest levels of expression in vitro. The inclusion of a hybrid intron 3 to the promoter further increased expression 1.6-fold. The addition of a region of the CMV enhancer 5' to several weak promoters increased expression 8- to 67-fold, and co-transfection with a second plasmid encoding a chimeric transcription factor also enhanced expression. On the basis of these results, the CMV promoter, the hybrid intron, and the BGH polyadenylation signal were selected for consistent high level expression in vitro and in the mouse lung. However, expression was transient, with greater than 60% loss of activity in the first 7 days. This transient expression was not specific to CMV promoter-containing plasmids, because plasmids containing other heterologous promoters showed a similar profile of transient expression in vivo. These comparative analyses begin to provide a basis for the development of optimized expression plasmids for gene therapy of lung diseases.
This paper references
Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy.
X. Liang (1996)
Haemophiliacs seek compensation
N. Moran (1995)
Persistence of plasmid DNA and expression in rat brain cells in vivo
S. Jiao (1992)
A novel series of amphiphilic imidazolinium compounds for in vitro and in vivo gene delivery.
I. Solodin (1995)
A generic intron increases gene expression in transgenic mice.
T. Choi (1991)
Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy.
H. San (1993)
Cationic liposome-mediated gene transfer.
X. Gao (1995)
Lung-specific direct in vivo gene transfer with recombinant plasmid DNA.
M. Tsan (1995)
Powerful and versatile enhancer-promoter unit for mammalian expression vectors.
M. K. Foecking (1986)
A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice.
P. Shockett (1995)
In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment.
L. Cheng (1993)
Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene.
M. Abe (1993)
Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements.
B. Liu (1992)
The human ubiquitin gene family: structure of a gene and pseudogenes from the Ub B subfamily.
R. Baker (1987)
Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle.
J. Wolff (1992)
Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo.
F. Guo (1995)
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.
S. Malley (1994)
Cationic Liposome-mediated Intravenous Gene Delivery (*)
Y. Liu (1995)
Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: a phase I trial of safety and efficacy in the nasal airway.
E. Sorscher (1994)
Improved Cationic Lipid Formulations for In Vivo Gene Therapy
P. Felgner (1995)
Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences.
S. Carswell (1989)
Potentiation of cationic liposome-mediated gene delivery by polycations.
X. Gao (1996)
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
J. Riordan (1989)
Novel Polyaminolipids Enhance the Cellular Uptake of Oligonucleotides (*)
J. K. Guy-Caffey (1995)
cis-acting elements that confer lung epithelial cell expression of the CC10 gene.
B. Stripp (1992)
An improved plasmid DNA expression vector for direct injection into skeletal muscle.
J. Hartikka (1996)
Gene transfer with a series of lipophilic DNA-binding molecules.
J. S. Rémy (1994)
In vitro polyadenylation is stimulated by the presence of an upstream intron.
M. Niwa (1990)
The 3'-flanking sequence of the bovine growth hormone gene contains novel elements required for efficient and accurate polyadenylation.
E. Goodwin (1992)
Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells.
J. Berger (1988)
Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung.
E. Lee (1996)
The therapeutic potential of the human cystic fibrosis transmembrane conductance regulator gene.
A. Pavirani (1997)
Definition of an efficient synthetic poly(A) site.
N. Levitt (1989)
Interleukin-8 gene expression in human bronchial epithelial cells.
H. Nakamura (1991)
Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations.
J. Felgner (1994)
Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter.
J. Harms (1995)
Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
Natasha J. Caplen (1995)
Enhancer and promoter chimeras in plasmids designed for intramuscular injection: a comparative in vivo and in vitro study.
K. Barnhart (1998)
Activation of gene expression is adversely affected at high multiplicities of linked simian virus 40 enhancer.
R. Kumar (1986)
Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins.
G. Wong (1985)
A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA.
J. G. Lewis (1996)
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
M. Gossen (1992)
Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis
J. Zabner (1993)
GAL4-VP16 is an unusually potent transcriptional activator
I. Sadowski (1988)
Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA.
M. T. Huang (1990)
Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells.
B. S. Chapman (1991)
Cis-acting sequences from a human surfactant protein gene confer pulmonary-specific gene expression in transgenic mice.
T. Korfhagen (1990)

This paper is referenced by
Investigation of hrDNA targeting vector-mediated tumor-specific suicide gene therapy for hepatocellular carcinoma
L. Wang (2006)
Adeno‐associated virus gene transfer in Morquio A disease – effect of promoters and sulfatase‐modifying factor 1
C. J. Alméciga-Díaz (2010)
Heat-inducible amplifier vector for high-level expression of granulocyte-macrophage colony-stimulating factor
P. Dammeyer (2006)
The human elongation factor 1 alpha (EF-1 alpha) first intron highly enhances expression of foreign genes from the murine cytomegalovirus promoter.
Seon-Young Kim (2002)
Gene Therapy and Gene Transfer Approaches for Acute Lung Injury
Daniel Weiss (2002)
Gene transfer vector development to treat lung disease: The use of a dual-function Lentiviral vector containing ENaC RNAi and the CFTR gene to treat Cystic Fibrosis lung disaease
R. Harding-Smith (2014)
Pharmaceutical gene medicines for non-viral gene therapy
A. Rolland (1999)
Increased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA Vaccine
K. Ljungberg (2007)
Pushing the Right Buttons: Improving Efficacy of Therapeutic DNA Vectors.
A. Hacobian (2017)
The impact of intragenic CpG content on gene expression
A. P. Bauer (2010)
Nonviral approaches satisfying various requirements for effective in vivo gene therapy.
M. Nishikawa (2002)
Genetic Engineering: Altering the Threads of Life
Tanim Arpit Singh (2020)
Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models.
M. Lanuti (2000)
Pushing the Right Buttons: Improving Efficacy of Therapeutic DNA Vectors
HacobianAra (2017)
Increased duration of transgene expression in the lung with plasmid DNA vectors harboring adenovirus E4 open reading frame 3.
N. Yew (1999)
Novel ubiquitous promoters and expression-vector optimization in ascidian embryos
K. Shimai (2008)
Examining multiple cellular pathways at once using multiplex hextuple luciferase assaying
Alejandro Sarrion-Perdigones (2019)
Improving transcriptional activity of human cytomegalovirus major immediate-early promoter by mutating NF-κB binding sites.
D. Wang (2018)
Pharmaceutical perspectives of nonviral gene therapy.
R. Mahato (1999)
Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA.
M. McCluskie (1998)
Die Bedeutung intragenischer CpG Dinukleotide für die in vitro Expression von Immunmodulatoren
Asli Bauer (2009)
CMV enhancer/human PDGF-β promoter for neuron-specific transgene expression
B. Liu (2004)
Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo.
A. Bielinska (2000)
pCOR: a new design of plasmid vectors for nonviral gene therapy
F. Soubrier (1999)
Comparison of promoter region constructs for in vivo intramuscular expression
E. Fabre (2006)
A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia.
L. Ostedgaard (2005)
Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides*
K. Friedman (1999)
Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays
T. M. Buck (2020)
High‐level gene transfer to the cornea using electroporation
K. Blair-Parks (2002)
Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl- transport and overexpression can generate basolateral CFTR.
S. Farmen (2005)
Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor1α promoter
D R Gill (2001)
Cationic Lipids for Lung Gene Therapy
R. Scheule (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar